![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Fluidigm’s Advanta Dx COVID-19 EASE Assay Snags FDA Emergency Use Authorization
Fluidigm’s Advanta Dx COVID-19 EASE Assay Snags FDA Emergency Use Authorization
South San Francisco, Calif.-based Fluidigm’s Advanta Dx COVID-19 EASE assay has received Emergency Use Authorization from the FDA.
The polymerase chain-reaction (PCR) test is authorized for detection of nucleic acid from the SARS-CoV-2 virus in nasal swab specimens from individuals suspected by a healthcare provider to have COVID-19.
The real-time reverse transcription PCR test is limited to laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 and meet the requirements to perform high-complexity tests.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct